Krystal Biotech (NASDAQ:KRYS) Hits New 1-Year High – What’s Next?

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) reached a new 52-week high on Thursday . The company traded as high as $221.97 and last traded at $222.6410, with a volume of 206466 shares trading hands. The stock had previously closed at $217.46.

Wall Street Analyst Weigh In

Several research analysts have weighed in on KRYS shares. Bank of America boosted their price target on Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Guggenheim set a $224.00 target price on shares of Krystal Biotech and gave the stock a “buy” rating in a report on Friday, October 17th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Krystal Biotech in a research note on Monday. Citigroup boosted their price objective on shares of Krystal Biotech from $166.00 to $198.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 4th. Finally, Chardan Capital lifted their price target on Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Krystal Biotech presently has a consensus rating of “Moderate Buy” and an average target price of $228.14.

Krystal Biotech Stock Performance

The company’s fifty day simple moving average is $195.38 and its two-hundred day simple moving average is $161.38. The stock has a market capitalization of $6.43 billion, a P/E ratio of 33.28 and a beta of 0.48.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 3rd. The company reported $2.66 EPS for the quarter, beating the consensus estimate of $1.12 by $1.54. The company had revenue of $97.80 million for the quarter, compared to the consensus estimate of $93.72 million. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%. On average, research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Institutional Trading of Krystal Biotech

A number of institutional investors have recently bought and sold shares of the business. Jefferies Financial Group Inc. bought a new position in shares of Krystal Biotech during the first quarter worth approximately $757,000. PNC Financial Services Group Inc. increased its stake in Krystal Biotech by 27.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,141 shares of the company’s stock worth $386,000 after acquiring an additional 461 shares during the period. Blair William & Co. IL increased its stake in Krystal Biotech by 26.7% during the 1st quarter. Blair William & Co. IL now owns 9,433 shares of the company’s stock worth $1,701,000 after acquiring an additional 1,990 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Krystal Biotech by 3.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 250,514 shares of the company’s stock valued at $45,168,000 after acquiring an additional 7,344 shares in the last quarter. Finally, Beacon Harbor Wealth Advisors Inc. bought a new stake in shares of Krystal Biotech during the 1st quarter valued at $5,812,000. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).